Oxytocin substitution therapy in patients with AVP deficiency (central diabetes insipidus): study protocol of a double-blind, randomised placebo-controlled trial

What Was Tested

The paper reports a study of Oxytocin, published as a clinical study.

Arginine vasopressin (AVP) and oxytocin (OXT) are both hormones released from the posterior pituitary.

While AVP primarily regulates water reabsorption in the kidneys, OXT plays a key role in socioemotional functioning.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

This is a randomised, double-blind, placebo-controlled, parallel-group trial enrolling adults with AVP-D.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Oxytocin, giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Secondary outcomes include empathy, stress reactivity, neuroimaging markers of amygdala activity, additional psychological measures, metabolic parameters and safety outcomes, including hyponatraemia.

Analyses will follow the intention-to-treat principle, with Fisher's exact test used for the primary outcome and mixed-effects models for secondary endpoints.

What Was Measured

Topics PubMed links to this paper include Oxytocin, Diabetes Insipidus, Neurogenic, Randomized Controlled Trials as Topic, Arginine Vasopressin, Anxiety and Emotions.

The authors tagged it with the keywords Clinical Trial, Clinical trials, General endocrinology and Pituitary disorders.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin.

The publication is from 2026 (BMJ open), a journal based in England.

More context: the Oxytocin compound page, all human trials.